1. Home
  2. ENTX vs SFWL Comparison

ENTX vs SFWL Comparison

Compare ENTX & SFWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTX
  • SFWL
  • Stock Information
  • Founded
  • ENTX 2010
  • SFWL 2001
  • Country
  • ENTX Israel
  • SFWL China
  • Employees
  • ENTX N/A
  • SFWL N/A
  • Industry
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • SFWL Trucking Freight/Courier Services
  • Sector
  • ENTX Health Care
  • SFWL Industrials
  • Exchange
  • ENTX Nasdaq
  • SFWL Nasdaq
  • Market Cap
  • ENTX 90.2M
  • SFWL 80.8M
  • IPO Year
  • ENTX 2018
  • SFWL 2023
  • Fundamental
  • Price
  • ENTX $2.55
  • SFWL $1.02
  • Analyst Decision
  • ENTX Strong Buy
  • SFWL
  • Analyst Count
  • ENTX 1
  • SFWL 0
  • Target Price
  • ENTX $10.00
  • SFWL N/A
  • AVG Volume (30 Days)
  • ENTX 86.5K
  • SFWL 20.5K
  • Earning Date
  • ENTX 03-07-2025
  • SFWL 03-27-2025
  • Dividend Yield
  • ENTX N/A
  • SFWL N/A
  • EPS Growth
  • ENTX N/A
  • SFWL N/A
  • EPS
  • ENTX N/A
  • SFWL 0.11
  • Revenue
  • ENTX $99,000.00
  • SFWL $446,281,000.00
  • Revenue This Year
  • ENTX N/A
  • SFWL N/A
  • Revenue Next Year
  • ENTX N/A
  • SFWL N/A
  • P/E Ratio
  • ENTX N/A
  • SFWL $9.47
  • Revenue Growth
  • ENTX 607.14
  • SFWL 14.80
  • 52 Week Low
  • ENTX $0.71
  • SFWL $0.81
  • 52 Week High
  • ENTX $3.35
  • SFWL $2.23
  • Technical
  • Relative Strength Index (RSI)
  • ENTX 61.93
  • SFWL 46.64
  • Support Level
  • ENTX $2.00
  • SFWL $0.98
  • Resistance Level
  • ENTX $2.62
  • SFWL $1.08
  • Average True Range (ATR)
  • ENTX 0.18
  • SFWL 0.05
  • MACD
  • ENTX 0.01
  • SFWL 0.00
  • Stochastic Oscillator
  • ENTX 96.77
  • SFWL 48.00

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About SFWL Shengfeng Development Limited

Shengfeng Development Ltd is a holding company. The company offers contract logistics services comprising planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services. The integrated logistics solution services of the company are comprised of three segments: B2B freight transportation; cloud storage; and value-added services.

Share on Social Networks: